The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

Start Date01 Dec 2022

Sponsor / Collaborator

NYU Langone Health

[+1]

NCT02450279 / TerminatedNot ApplicableIIT

Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation

Many devices are available for nebulising drug solution during invasive mechanical ventilation. Vibrating-mesh nebulizers ensure the highest lung deposition output. A recent international survey on aerosol therapy during mechanical ventilation (Ehrmann et al. 2013) reported that jet nebulizers remained the mostly used.
The aim of this study is to compare lung deposition of a radiolabeled administered with both nebulizers during invasive mechanical ventilation by planar scintigraphy.

Start Date01 Mar 2016

Sponsor / Collaborator

Cliniques Universitaires Saint-Luc

NCT02429817 / CompletedNot ApplicableIIT

Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula

Vibrating-mesh nebulizers ensure currently the best deposition output and are recommended in routine use in intensive care unit. However, jet nebulizers remain the most frequently used nebulizers.
On a bench study, aerosol delivery through a high flow nasal cannula (HFNC) was increased using a vibrating-mesh nebulizer as compared to a jet nebulizer.
Lung distribution of nebulized particles delivered through a HFNC has never been investigated in vivo. The aim of this study was to compare aerosol lung distribution with both nebulizers through a HFNC by SPECT-CT.

Start Date01 Apr 2015

Sponsor / Collaborator

Cliniques Universitaires Saint-Luc

100 Clinical Results associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

100 Translational Medicine associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

100 Patents (Medical) associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

4,436

Literatures (Medical) associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

01 Jan 2025·Journal of Environmental Sciences

Enhancing microbial superoxide generation and conversion to hydroxyl radicals for enhanced bioremediation using iron-binding ligands

Article

Author: Qu, Jiuhui ; Ning, Xue ; Wang, Aijie ; Liang, Jinsong ; Wang, Yuhan

Harnessing bacteria for superoxide production in bioremediation holds immense promise, yet its practical application is hindered by slow production rates and the relatively weak redox potential of superoxide. This study delves into a cost-effective approach to amplify superoxide production using an Arthrobacter strain, a prevalent soil bacterial genus. Our research reveals that introducing a carbon source along with specific iron-binding ligands, including deferoxamine (DFO), diethylenetriamine pentaacetate (DTPA), citrate, and oxalate, robustly augments microbial superoxide generation. Moreover, our findings suggest that these iron-binding ligands play a pivotal role in converting superoxide into hydroxyl radicals by modulating the electron transfer rate between Fe(III)/Fe(II) and superoxide. Remarkably, among the tested ligands, only DTPA emerges as a potent promoter of this conversion process when complexed with Fe(III). We identify an optimal Fe(III) to DTPA ratio of approximately 1:1 for enhancing hydroxyl radical production within the Arthrobacter culture. This research underscores the efficacy of simultaneously introducing carbon sources and DTPA in facilitating superoxide production and its subsequent conversion to hydroxyl radicals, significantly elevating bioremediation performance. Furthermore, our study reveals that DTPA augments superoxide production in cultures of diverse soils, with various soil microorganisms beyond Arthrobacter identified as contributors to superoxide generation. This emphasizes the universal applicability of DTPA across multiple bacterial genera. In conclusion, our study introduces a promising methodology for enhancing microbial superoxide production and its conversion into hydroxyl radicals. These findings hold substantial implications for the deployment of microbial reactive oxygen species in bioremediation, offering innovative solutions for addressing environmental contamination challenges.

01 Dec 2024·Environmental Research

Selectively recovering rare earth elements with carboxyl immobilized metal-organic framework from ammonium-rich wastewater

Article

Author: Wang, Qiang ; Liu, Zhigong ; Zhao, Feiping ; Tang, Chong-Jian ; Zhang, Meng ; Yao, Fubing ; Gao, Tianyu ; Wang, Haiying

The material with high adsorption capacity and selectivity is essential for recovering rare earth elements (REE_S) from ammonium (NH₄⁺-N)-rich wastewater. Although the emerging metal-organic framework (MOF) has gained intensive attention in REE_S recovery, there are scientific difficulties unsolved regarding restricted adsorption capacity and selectivity, hindering its extensive engineering applications. In this work, a diethylenetriamine pentaacetic (DTPA)-modified MOF material (MIL-101(Cr)-NH-DTPA) was prepared through an amidation reaction. The MIL-101(Cr)-NH-DTPA showed enhanced adsorption capacity for La(III) (69.78 mg g^-1), Eu(III) (103.01 mg g^-1) and Er(III) (83.41 mg g^-1). The adsorption isotherm and physical chemistry of materials indicated that the adsorption of REEs with MIL-101(Cr)-NH-DTPA was achieved via complexation instead of electrostatic adsorption. Such complexation reaction was principally governed by -COOH instead of -NH₂ or -NO₂. Meanwhile, the resulting material remained in its superior activity even after five cycles. Such a constructed adsorbent also exhibited excellent selective adsorption activity for La(III), Eu(III), and Er(III), with removal efficiency reaching 70% in NH₄⁺-N concentrations ranging from 100 to 1500 mg L^-1. This work offers underlying guidelines for exploitation an adsorbent for REEs recovery from wastewater.

01 Dec 2024·Science of The Total Environment

Delving into nitrogen and phosphorus dynamics in shallow eutrophic lakes: Multi-interface response to freeze-thaw cycles

Article

Author: Yu, Ruihong ; Wang, Xiaozhuang ; Cao, Zhengxu ; Geng, Yue ; Sun, Heyang ; Li, Xiangwei

Assessing the impact of freeze-thaw cycles on nutrient transfer in lakes is crucial for addressing the global eutrophication of freshwater ecosystems in cold and arid regions. However, available information about the dynamics of nitrogen (N) and phosphorus (P) release during intact freeze-thaw cycles, especially in the sediment-porewater-water column continuum of lakes, is limited. This study collected the samples during ice-covered (January) and non-ice-covered (April, July, and October) periods. The changes in total nitrogen (TN) and total phosphorus (TP) were analyzed to estimate their release fluxes from the sediment-water interface. Both redundancy analysis (RDA) and variance partitioning analysis (VPA) were used to explore the effects of environmental variables on N and P. The results indicated that during the ice-covered period (ICP), the surface water content of different forms of N and P was lower than that of the overlying water, whereas the opposite was true during the non-ice-covered period (NICP). The overall trend for the different forms of N was TN > DIN > NH₄-N > NO₃-N > NO₂-N, and for P, it was TP > PP > DTP > DOP>DIP. The vertical profiles of the porewater TN and TP generally demonstrated an increase followed by a decrease from the surface to the bottom, with an inflection point at 15 cm. Sediment TN and TP trends over time matched porewater trends, with both being spatially highest at the lake inlet. ICP sediments acted as sinks for TN and TP, and NICP sediments acted as sources. N and P in the water column were significantly correlated mainly with physicochemical indicators, whereas sediment contributed positively to TN and TP in the porewater. VPA indicated that environmental factors explained 46.45 % of the variation in TN and TP in the porewater. These findings emphasize the importance of freeze-thaw cycling processes in driving N and P nutrient enrichment, source-sink effects, and multi-media coupling in shallow lakes in arid plateau regions.

News (Medical) associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

11 Jun 2024

·www.prnewswire.com

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Radiation Therapy

22 Jan 2024

·www.medicaldesignandoutsourcing.com

Potential bioelectric applications of organic mixed ionic–electronic conductors

Researchers in Korea say they found a way to potentially accelerate the development of high-performance organic electrochemical transistor devices with tunable transient responses. Organic mixed ionic-electronic conductors (OMIECs) offer potential bioelectric applications. Researchers at the Gwangju Institute of Science and Technology (GIST) used the transistors as platforms for testing the molecular orientation and ion injection directionality-dependent transient properties of OMIECs. Potential applications for OMIECs include computing and bio-fuel cells in addition to bioelectronics. The researchers say that, to ensure a wider acceptance of these materials, there remains a need to diversify their properties and develop techniques for application-specific OMIEC tailoring. They cite a “severe” lack of research on the molecular orientation-dependent transient behaviors of such conductors. The team at GIST, consisting of researchers from both Korea and the UK, set out to bridge the gap in understanding there. Professor Myung-Han Yoon from the GIST School of Materials Science and Engineering led the researchers. They explored the transient behaviors of OMIECs governed by variations in molecular orientation with the help of an organic electrochemical transistor (OECT). “OECTs are known to mimic the computing mechanisms of neurons and synapses in spiking neural networks (SNNs) and are thus considered promising,” said Yoon. “To aid the growing interest in exploring the dynamic behaviors of OECTs at the frequency domain, we focused on an aspect that is often overlooked. We decided to investigate the correlation between backbone planarity-dependent molecular orientation and transient OECT characteristics.” First, they synthesized two new 1,4-dithienylphenylene (DTP)-based OMEICs, DTP-2T and DTP-P, with co-monomer units, 2,2’-bithiophene and phenylene, respectively. According to GIST, the polymers comprised the same ionic and electronic properties. However, by manipulating the polymer backbone planarity, the researchers controlled the dominant molecular orientation of the mixed conductor system. This polymer then successfully helped to fabricate OECT devices. The team found that the polymers showed similar electrochemical properties despite having different molecular orientations. They then changed the ion injection direction when observing a certain current/voltage during the analysis. In the analysis, the researchers saw that ion injection relative to the molecular orientation affected the length of the ion drift pathway. This, in turn, resulted in peculiar transient responses in OECT devices. The team believes it could use its research to facilitate the design and development of advanced organic mixed conductor materials for biomolecular and biosignal sensors. “OECT-based SNN architectures are anticipated to replace current computing systems in the future by increasing computation speed and reducing energy consumption,” Yoon said. “Our findings are expected to facilitate the realization of SNN-based computing systems soon.”

13 Dec 2022

·www.prnewswire.com

Anti-radiation Drugs Market to Reach US$ 9.6 Bn by 2031, TMR Study

Rise in investment in R&D by pharma and biotech companies for the development of effective drugs for acute radiation syndrome or ARS propels market growth Increase in efforts by pharmaceutical companies to develop innovative radiopharmaceutical products augments industry development WILMINGTON, Del., Dec. 13, 2022 /PRNewswire/ -- The global anti-radiation drugs market was valued at US$ 3.4 Bn in 2021 and is anticipated to grow at a CAGR of 9.9% from 2022 to 2031. Increase in demand for drugs, such as Prussian Blue, Diethylenetriamine pentaacetate or DTPA, and potassium iodide or KI, to block the concentration and absorption of radioactive iodide in the human thyroid gland propels market growth. Moreover, the threat of nuclear disaster looms over humanity owing to the increasing number of nuclear weapons and warheads in the world. Therefore, rise in efforts by countries to be prepared for nuclear or radioactive disasters by developing radiation countermeasures is augmenting market development. Quick Delivery Available | Buy this Premium Research Report – Anti-radiation Drugs Market - Key Findings of the Report Rise in Prevalence of Acute Radiation Syndrome: As per market research, the acute radiation syndrome (ARS) segment dominated the industry in 2021. ARS, at present, is considered the most crucial and challenging aspect regarding public health and well-being in a likely case of radiological or nuclear incidence. Apart from ARS, increasing incidence of cancer is boosting market growth. Growing Demand for Potassium Iodide Products: Based on type of compound, the potassium iodide (KI) segment led the global market in 2021. Tablets and drug formulations manufactured using potassium iodide compounds offer excellent protection against certain cases of exposure to harmful radiations. Furthermore, being a highly soluble form of iodine, KI compounds are the widely used active pharmaceutical ingredients in the radiopharmaceuticals industry. Apart from this, owing to its recorded effectiveness and safe nature in treating patients suffering from radiation exposure in the Chernobyl disaster, KI compounds are considered to be safest in treating ARS, even in small children. Anti-radiation Drugs Market – Growth Drivers Surge in incidence of cancer propels demand for anti-radiation drugs Rise in prevalence of acute radiation syndrome or ARS Increase in concerns pertaining to usage of nuclear weapons in global conflict is anticipated to augment market growth in the next few years Ask for References – Anti-radiation Drugs Market - Key Players Key players and manufacturers assessed in this market research are Arco Pharmaceuticals LLC, Cellphire, Inc., Darnitsa, Humanetics Corporation, Myelo Therapeutics GmbH, Pluri, Inc., Anbex Inc., BTG Pharmaceuticals LLC, Chrysalis BioTherapeutics, Inc., Enzychem Lifesciences Corporation, Mission Pharmacal Company, and Partner Therapeutics. The global market is consolidated, with the presence of a relatively small number of leading and tier 1 players. These players adopt growth strategies, such as merger & acquisition, and launch of new products, to increase market share. Manufacturers are also focused on increasing research & development initiatives and projects in order to design, develop, and test new compounds and drug formulations that display enhanced anti-radiation properties. Anti-radiation Drugs Market - Regional Growth Assessment North America is anticipated to lead the global industry in the next decade. Key factors driving the market in the region are increase in the number of radiation treatment facilities and rise in investment by stakeholders in the anti-radiation medical devices industry. Furthermore, growing participation and significant role played by the U.S. Government for developing biologically produced medical countermeasures for acute radiation syndrome are expected to propel the market demand. Anti-radiation Drugs Market: Segmentation Anti-radiation Drugs Market, by Compound Potassium Iodide (KI) Prussian Blue DTPA (Diethylenetriamine Pentaacetate) Others Anti-radiation Drugs Market, by Application Acute Radiation Syndrome (ARS) Cancer Treatment Radiation Exposure Others Anti-radiation Drugs Market, by Distribution Channel Hospital Pharmacies Retail Pharmacies Others Anti-radiation Drugs Market, by Region North America Latin America Europe Asia Pacific Middle East & Africa Make an Enquiry Before Buying – Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research: Halal and Kosher Empty Capsules Market: Halal and Kosher Empty Capsules Market is anticipated to reach more than US$ 2.9 Bn by the end of 2031 and to grow at a CAGR of 8.0% from 2022 to 2031. Alzheimer's Disease Biomarkers Market: Alzheimer's Disease Biomarkers Marketis anticipated to grow at a CAGR of 7.3% from 2022 to 2031 and reach more than US$ 1.7 Bn by the end of 2031. Animal Drug Compounding Market: The global animal drug compounding market is anticipated to be reach more than US$ 2.4 Bn by the end of 2031 at a CAGR of 7.4% between 2022 and 2031. Primary Progressive Multiple Sclerosis Treatment Market: Primary Progressive Multiple Sclerosis Treatment Market is projected to advance at a CAGR of 14.7% from 2022 to 2031 ad reach more than US$ 3.2 Bn by the end of 2031. Fusion Inhibitors Market: Fusion Inhibitors Market is projected to advance at a CAGR of 14.2% from 2022 to 2031 and reach more than US$ 7.2 Bn by 2031. Rare Kidney Diseases Treatment Market: Rare Kidney Diseases Treatment Market is projected to grow at a CAGR of 5.8% from 2022 to 2031 and reach more than US$ 4.6 Bn by the end of 2031. Asthma Treatment Market: Asthma Treatment Market is projected to grow at a CAGR of 3.7% from 2022 to 2031 and reach more than US$ 34.5 Bn by the end of 2031. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Nikhil Sawlani Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

Radiation Therapy

100 Deals associated with Technetium (99mTc) Diethylenetriamine Pentaacetic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	Technetium (99mTc) Diethylenetriamine Pentaacetic Acid	-	DB14007

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lung Diseases	US	Jubilant Draximage, Inc.Startup	26 Dec 2017
Brain Diseases	US	Jubilant Draximage, Inc.Startup	29 Dec 1989
Kidney Diseases	US	Jubilant Draximage, Inc.Startup	29 Dec 1989
Diagnostic agents	JP	PDRadiopharma, Inc.	22 May 1979

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	-	University of California San Diego	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2022	Not Applicable	Hydronephrosis	-	99mTc-DTPA (Mild hydronephrosis group)	lypbeacest(czkmzdprce) = plzxuxvccl sqphentoxd (vzvcdjddix ) View more	-	08 Aug 2022
				99mTc-DTPA (Moderate hydronephrosis group)	lypbeacest(czkmzdprce) = clhblahchy sqphentoxd (vzvcdjddix ) View more
SNMMI2022	Not Applicable	-	-	99mTc-L,L EC	(ydjpvnsmsn) = kxymbjkcql sqfcfxurng (umwtfzywhz, 13.77)	-	08 Aug 2022
				99mTc-DTPA	(ydjpvnsmsn) = llboygtmnt sqfcfxurng (umwtfzywhz, 16.74)
ERS2021	Not Applicable	Scleroderma, Diffuse KL-6 \| SP-D	58	Tc99m – DTPA aerosols	nkiawysfdx(owlpozsgay) = czkytxhbpw lpjdccaatn (tmmiboxxkm, 25.7)	Positive	05 Sep 2021
SNMMI2021	Not Applicable	Complication	-	99m Tc-DTPA (99mTc-DTPA scintigraphy)	yrtxfwqdca(tuuohrvwjv) = srbfcxyljr wturvpoomz (bypzgbibig ) View more	-	18 May 2021
NCT01027845 (CTgov)	Phase 3	Streptococcal Infections	360	Pneumococcal vaccine GSK1024850A+DTPa (10Pn Group)	cxlxixiipf(qooewiyeqb) = qkvdrtyhzw iyfmreshvj (tjlstgugqo, cpclcfgsfz - nweaybkunq) View more	-	29 Nov 2019
				DTPa (DTPa Group)	cxlxixiipf(qooewiyeqb) = vsskwkjrci iyfmreshvj (tjlstgugqo, bofdqhwhna - jflbjdcbxa) View more
SNMMI2018	Not Applicable	Brain Death	-	Tc-99m DTPA (Equivocal flow)	hcwtqalkva(vnmfffgtsx) = fyyxqqhxwk htcqwgimza (kaqqxzuhls )	-	23 May 2018
				Tc-99m DTPA (Definite flow)	hcwtqalkva(vnmfffgtsx) = oegiqxkrra htcqwgimza (kaqqxzuhls )
AUA2017	Not Applicable	-	699	DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 1)	fwaqxtxpho(myluvhgimr) = dgmzydpxmd ybmhvmaiea (onprduqppn ) View more	-	01 Apr 2017
				DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 2)	fwaqxtxpho(myluvhgimr) = ryhzpsnswl ybmhvmaiea (onprduqppn ) View more
SNMMI2016	Not Applicable	-	-	99m Tc-DTPA (99mTc-DTPA renal scintigraphy before urinary enhanced CT scan)	(aumyvuqvxb) = clumncknii sfgcmqmoqf (efbdhjdjfg ) View more	-	24 May 2016
				99m Tc-DTPA (99mTc-DTPA renal scintigraphy after urinary enhanced CT scan)	(aumyvuqvxb) = zjwpubcggz sfgcmqmoqf (efbdhjdjfg ) View more
SNMMI2016	Not Applicable	Urinary Calculi	-	Tc-99m DTPA (Urinary stone patients)	urrxjaarbc(ihnvsiebnj) = wedggkbqhw hfghjpdrnb (romevfgixg, 0.41) View more	Positive	24 May 2016
				Tc-99m DTPA (Kidney donors)	urrxjaarbc(ihnvsiebnj) = ozhnduztfu hfghjpdrnb (romevfgixg, 0.15) View more
Pubmed \| Clin Chest Med	Not Applicable	Pulmonary Cystic Fibrosis	-	DTPA (CF subjects)	mbxprjfidl(gvjfhgatzf) = dujwikjoza vvtifpwpzr (rghqssaktw )	-	01 Apr 2010
				DTPA (Control subjects)	mbxprjfidl(gvjfhgatzf) = wlujnoqewm vvtifpwpzr (rghqssaktw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis